Pictor Offer - an update
Three weeks ago I wrote to the subscribers to my Newsletters who had shown interest in our Pictor Offer. In it I reminded them that the lockdown here shows us Covid19 is worldwide and has far from disappeared, even in New Zealand.
Three weeks ago I wrote to the subscribers to my Newsletters who
had shown interest in our Pictor Offer. In it I reminded them that the
lockdown here shows us Covid19 is worldwide and has far from disappeared, even in New Zealand.
Well here we are (in Auckland) in lockdown again. So I thought it appropriate
to update all of you who subscribe to my Opportunities newsletters, with much
of the information I included in the email mentioned above.
Australian connection
First you’d be interested to know we’ve extended this Offer to Australia investors via my contacts
there. This will be live in the next few days.
And with more, and larger, qualifying “Wholesale Investors” in Australia, I
expect this will make a big contribution to shortly completing this capital
raising round.
Other news
Meanwhile developments since my last Newsletter include the following:
Dr Tadd S. Lazarus has joined their team as Chief Medical
Officer. As CMO at Roche Diagnostics, Dr Lazarus oversaw the
successful development of a specialised diagnostic test kit for HIV.
The business is planning a clinical trial in New Zealand that will show how the
Pictor test could be used to identify persons at the border who do not require 14 days
isolation, because;
- they are antibody positive as a consequence of being either vaccinated;
- or were previously infected, and are now free of the infection.
Such an allowance will
benefit everyone; including visitors here as well as New Zealanders wishing to
travel outside the country for short term business or holidays.
The Company is now calling for volunteers who are willing to provide a blood
sample to participate in this trial. Volunteers are required who have:
- Previously been infected but now recovered (30 persons).
- Vaccinated with first dose. (30 persons).
- Vaccinated with both doses (30 persons).
- Neither been infected nor vaccinated (120 persons).
Pictor’s manufacturing capacity has been markedly expanded with the successful commissioning of the iONE1200 arrayer imported from Germany.
Patents
Pictor’s patent for the multiplex COVID-19 antibody test has now entered the PCT phase, which will provide international protection to 150 countries that are party to the PCT treaty.
Meanwhile the patent has been approved by the U.S. Patent Office as one of a limited number of COVID-19 patents that will be fast tracked for approval in the U.S. – and that’s in as little as 6 months instead of the usual 2 to 3 years.
Pictor and German company Scienion, have entered into a collaboration by which Scienion’s CL2 reader will be sold to U.S. labs as part of the platform for using Pictor’s COVID-19 antibody test. The companies will jointly promote the platform to the U.S. market.
How to participate in the ownership of this business
The Information Memorandum for this Offer is available now – as are financial forecasts and a new slide deck describing the business. For copies of these reply to this email and please include your phone number.
If you’d like to know more, reply to this email or call me. Or if you’d like to contact Howard direct, his email is h.moore@pictordx.com and his phone number +64 21 203 1607
.............................................................................................................................................................................................................
The above investment is not
an offer of financial products that requires disclosure under the Financial
Markets Conduct Act 2013 (Act) and is available only to wholesale investors as
defined by that Act. It is intended for distribution only to selected
people to whom, under the relevant laws, it can be lawfully distributed. It
cannot be distributed in any other jurisdiction, or to any other people. It is
not an offer or solicitations in any jurisdiction in which such offers or
solicitations are not authorised, or in which the person making such offers or
solicitations are not qualified to do so, or to any person to whom it is
unlawful to make such offers or solicitations. Any representation to the
contrary would be unlawful. No action has been taken by any person that would
permit a public offering in any jurisdiction where action for that purpose
would be required.
Cheers
John Paine B.Sc.,
Dip BIA
TBK Capital Limited
Level 10,120 Albert Street
Auckland 1010, New Zealand
Phone +64 9 307 3257
Mobile +64 21 902 901
Email john.paine@tbkcapital.co.nz
For more information, please click the contact button below to send us a message.
⇑ back to top